Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.75 USD | -0.45% |
|
-1.07% | -7.57% |
05-23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
05-23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.57% | 1.47B | |
+7.39% | 72.09B | |
+15.93% | 9.05B | |
-22.81% | 4.4B | |
+17.59% | 4.39B | |
+25.93% | 3.94B | |
+4.64% | 2.1B | |
+9.09% | 1.97B | |
-36.86% | 1.87B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals : to Buy Adamas for $400 Million Upfront Plus Further Boost Based on Parkinson's Disease Drug Sales